ADC Manufacturing Demand Outpaces Capacity in US Market

“Twenty years ago, who knew that ADCs and next-generation bioconjugates were going to be so exciting, so successful?”

Campbell Bunce, Chief Scientific Officer at Abzena, reflects on the strategic positioning that has placed his company at the forefront of one of pharma’s fastest-growing segments.

Campbell leads a global team spanning discovery, development, and GMP manufacturing at Abzena, where he has spent nearly a decade building the company’s capabilities in complex modalities. His background as an immunologist, combined with 18 years in biotech before joining Abzena, gives him a unique perspective on translating scientific innovation into commercial manufacturing reality.

In this conversation on the PharmaSource podcast, Campbell discusses Abzena’s strategic focus on antibody-drug conjugates (ADCs) and bioconjugates, the company’s approach to proprietary platform development, and how the CDMO is responding to increased demand driven by geopolitical manufacturing shifts and clinical successes in the space.

Read more.